Ultrasmall Nanoparticles Targeting Claudin-1 for Blood Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for delivering therapeutics or imaging agents across the blood-brain barrier lack specificity to regions of disease progression, leading to inefficient targeting of specific areas within the brain, which is a challenge in treating neurological disorders and imaging BBB permeability.
Innovation Solution
Development of ultrasmall nanoparticles conjugated with claudin or occludin polypeptides, specifically targeting claudin-1, which allows for targeted delivery or imaging across the BBB, enhancing accumulation and retention in regions with altered BBB integrity, such as the corpus callosum and hippocampus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If BBB permeable materials are used to increase delivery into the brain, then delivery efficiency is improved, but specificity towards regions of disease progression is lost
Solution Approach 1:
The nanoparticle surface is decorated with disease-specific peptide ligands that recognize and bind to receptors overexpressed in pathological regions (e.g., tumor-associated endothelial cells). This enables the same nanoparticle formulation to achieve both high BBB penetration and region-specific targeting by concentrating therapeutic payload only at disease sites through selective molecular recognition
Solution Approach 2:
The delivery system combines multiple functional components: BBB-penetrating nanoparticle core, disease-specific peptide ligands for targeting, and therapeutic payload. This composite structure integrates the BBB-crossing capability with region-specific targeting function, resolving the contradiction between general permeability and specific targeting
2Productivity
If nanoparticle size is reduced to enhance BBB penetration, then permeability is improved, but payload capacity is reduced
Solution Approach 1:
The nanoparticle employs a core-shell architecture where the core contains the therapeutic payload and the shell provides BBB-penetration functionality and targeting ligands. This nested structure allows small size for penetration while encapsulating sufficient payload within the core, effectively resolving the size-capacity trade-off
3Measurement precision
If targeting ligands are added to nanoparticles for specific BBB region targeting, then targeting specificity is improved, but device complexity is increased
Solution Approach 1:
The invention extracts and utilizes naturally occurring disease-specific molecular signatures (e.g., overexpressed receptors on tumor endothelial cells) as targeting ligands. By harnessing existing pathological biomarkers rather than engineering complex synthetic ligands, the system achieves high targeting specificity with minimal structural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles demonstrate high accumulation and retention in brain regions with age-induced BBB leakiness, directly correlating with claudin-1 expression, offering a tool for non-invasive imaging and site-specific therapeutic delivery.
Implementation Method 1
nanoparticles comprising a claudin or occludin polypeptide or portion thereof conjugated thereto
Data Source
AI summary
Described herein are nanoparticle compositions that can be used to target specific regions of the blood brain barrier (BBB). Such nanoparticle compositions can be used to deliver therapeutics to or across the BBB or to image the BBB or the permeability thereof.